Summary of initial hospitalizations and rehospitalizations after liso-cel administration
| . | All patients (n = 23) . | Dose level 1 (n = 9) . | Dose level 2 (n = 14) . |
|---|---|---|---|
| Patients with initial hospitalization for liso-cel infusion | 23 (100) | 9 (100) | 14 (100) |
| Duration of initial hospital stay, median (range), days* | 17 (8-75) | 16 (8-75) | 17.5 (8-75) |
| Patients with rehospitalization after liso-cel infusion | 12 (52) | 4 (44) | 8 (57) |
| Reasons for patient rehospitalization | |||
| Adverse events | 11 (48) | 3 (33) | 8 (57) |
| CRS and/or NE† | 5 (22) | 1 (11) | 4 (29) |
| CRS and NE | 2 (9) | 0 | 2 (14) |
| NE only | 3 (13) | 1 (11) | 2 (14) |
| Patients with ICU admissions‡ | 2 (9) | 1 (11) | 1 (7) |
| Duration of ICU stay, median (range), days | 11.5 (9-14) | 14 (9-9) | 9 (14-14) |
| . | All patients (n = 23) . | Dose level 1 (n = 9) . | Dose level 2 (n = 14) . |
|---|---|---|---|
| Patients with initial hospitalization for liso-cel infusion | 23 (100) | 9 (100) | 14 (100) |
| Duration of initial hospital stay, median (range), days* | 17 (8-75) | 16 (8-75) | 17.5 (8-75) |
| Patients with rehospitalization after liso-cel infusion | 12 (52) | 4 (44) | 8 (57) |
| Reasons for patient rehospitalization | |||
| Adverse events | 11 (48) | 3 (33) | 8 (57) |
| CRS and/or NE† | 5 (22) | 1 (11) | 4 (29) |
| CRS and NE | 2 (9) | 0 | 2 (14) |
| NE only | 3 (13) | 1 (11) | 2 (14) |
| Patients with ICU admissions‡ | 2 (9) | 1 (11) | 1 (7) |
| Duration of ICU stay, median (range), days | 11.5 (9-14) | 14 (9-9) | 9 (14-14) |
Only includes hospitalization from first liso-cel administration and excludes rehospitalization from retreatment. Data are expressed as n (%) unless otherwise specified.
ICU, intensive care unit.
Excludes ICU stay.
No patient was rehospitalized for CRS only.
Includes ICU admissions during initial hospitalization and rehospitalization.